<DOC>
	<DOCNO>NCT02172456</DOCNO>
	<brief_summary>Primary endpoint : whole lung deposition in-vivo distribution pattern 99mTc-labelled tiotropium powder formulation follow inhalation via HandiHalerTM healthy subject well patient mild , moderate severe COPD Secondary endpoint : pharmacokinetics , pharmacodynamics ( effect lung function ) , safety tolerability</brief_summary>
	<brief_title>Evaluation Lung Deposition Rate Distribution Pattern Tiotropium Via HandiHalerTM Healthy Subjects Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>healthy subject COPD patient : Males females 40 year age old . Subjects/Patients must able inhale medication HandiHalerTM Subjects/Patients must able perform studyrelated test include acceptable pulmonary function test , must able maintain record study period require protocol . All subjects/patients must sign Informed Consent Form prior participation trial accordance ICHGCP local legislation , i.e. , COPD patient must give write informed consent prior prestudy washout usual pulmonary medication . healthy subject : Normal spirometry evidence baseline FEV1 ≥ 80 % predict normal value age , height sex , FEV1 ≥ 70 % FVC Lifelong nonsmoker exsmokers nonsmoking period least five year maximum five packyears . COPD patient : All patient must diagnosis relatively stable chronic obstructive pulmonary disease must fulfil spirometric criterion respective subgroup : Mild COPD : 50 % ≤ FEV1 &lt; 70 % predict normal ; FEV1/FVC &lt; 70 % . Moderate COPD : 35 % ≤ FEV1 &lt; 50 % predict normal ; FEV1/FVC &lt; 70 % . Severe COPD : FEV1 &lt; 35 % predict normal ; FEV1/FVC &lt; 70 % . healthy subject COPD patient : Subjects patient clinically relevant abnormal baseline haematology , blood chemistry urinalysis , abnormality defines disease list exclusion criterion exclude . All subjects/patients serum glutamicoxaloacetic transaminase ( SGOT ) &gt; 80 IU/L , serum glutamicpyruvic transaminase ( SGPT ) &gt; 80 IU/L , bilirubin &gt; 2.0 mg/dL creatinine &gt; 2.0 mg/dL exclude regardless clinical condition . Repeat laboratory evaluation conduct subjects/patients . Subjects/Patients recent history ( i.e. , one year less ) myocardial infarction . Subjects/Patients cardiac arrhythmia require drug therapy hospitalise heart failure within past three year . Subjects/Patients know active tuberculosis . Subjects/Patients history cancer within last five year . Subjects/Patients history lifethreatening pulmonary obstruction , history cystic fibrosis bronchiectasis . Subjects/Patients undergone thoracotomy pulmonary resection . Patients upper respiratory infection past six week prior Screening Visit ( Visit 1 ) runin period Subjects/Patients know hypersensitivity anticholinergic drug , lactose component inhalation capsule delivery system Subjects/Patients know symptomatic prostatic hyperplasia bladder neck obstruction . Subjects/Patients know narrowangle glaucoma . Subjects/Patients history asthma , allergic rhinitis atopy total blood eosinophil count ≥ 600 mm3 . A repeat eosinophil count conduct subjects/patients . Subjects/Patients history and/or active significant alcohol drug abuse . Subjects/Patients take investigational drug within one month six half life ( whichever short ) prior Screening Visit ( Visit 1 ) . In addition , female subjects/patients : Pregnancy . Positive pregnancy test . No adequate contraception , e.g . oral contraceptive , sterilisation , intra uterine device ( IUD ) . Inability maintain adequate contraception whole study period . Lactation period . healthy subject : Subjects significant disease exclude . A significant disease define disease opinion investigator may either put subject risk participation study disease may influence result study subject 's ability participate study . Use drug might influence result trial ( within one week prior administration trial ) . COPD patient : Patients significant disease COPD exclude . A significant disease define disease opinion investigator may either put patient risk participation study disease may influence result study patient 's ability participate study . COPD patient regularly use daytime oxygen therapy one hour per day investigator 's opinion unable abstain use oxygen therapy . Patients currently pulmonary rehabilitation programme complete pulmonary rehabilitation programme six week prior Screening Visit ( Visit 1 ) Patients treated oral beta adrenergic longacting beta adrenergic salmeterol formoterol . Patients treat beta blocker . Patients treat antileukotrienes . Patients treat cromolyn sodium nedocromil sodium . Patients treated antihistamine ( H1receptor antagonists ) . Patients use oral corticosteroid medication unstable dos ( i.e. , less four week stable dose ) dose excess equivalent 10 mg prednisolone per day 20 mg every day . Patients treat monoamine oxidase inhibitor tricyclic antidepressant . Patients adequate washout period medication specify Section 4.2.2 study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>